ArticleScientific reports2025
Potential sustained production of polyhydroxyalkanoate copolymers using cyanobacteria microbiomes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The copolymer poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) is considered one of the most promising PHA candidates for bioplastics production, exhibiting superior physical properties than the homopolymer poly(3-hydroxybutyrate) (PHB). In this study, for the first time, PHBV was successfully produced under non-sterile conditions with Synechocystis sp. and Synechococcus sp. as the dominant cyanobacteria in microbiomes. A semi-continuous cultivation approach was employed, alternating between growth and accumulation phases over an extended period of 56 days. The process included valerate supplementation as an external carbon precursor, and the working volume was 2.5 L. Additionally, four independent repetitions of PHBV production and recovery were conducted. This methodology contrasts with conventional experiments, which typically involve only a single repetition, focus on isolated strains, and are limited to small-scale, short-term flask experiments. The maximum PHBV content reached 10.7%dcw, the highest achieved proportion of the monomer 3-hydroxyvalerate (HV) was 57.4%. Moreover, fluorescence microscopy images staining with Nile Blue positive validated that PHBV biosynthesis in cyanobacterial cells. Image quantification revealed that Synechococcus sp., produced larger PHBV granules (avg. 0.80 ± 0.13 μm) than Synechocystis sp. (avg. 0.52 ± 0.13 μm). Excessive valerate concentration at the start of the growth phases caused a certain inhibition, impairing both biomass productivity and nitrogen assimilation. Thus, optimizing valerate dosage is critical to balancing microbial metabolism and maximizing PHBV yield. This work demonstrates the potential feasibility of sustained and cyclic PHBV production and extraction, and establishing a scalable, eco-friendly biomanufacturing platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.